Background: In germline genetic testing, variants from understudied ancestries have been disproportionately classified as being of uncertain significance. We hypothesized that the rate of variant reclassification likewise differs by ancestry. Methods: Nonbenign variants in actionable genes were collected from consenting subjects undergoing genetic testing at two Southern California sites from September 1996 through December 2016. Variant reclassifications were recorded as they were received, until February 2017 or reclassification to benign. Excluding duplicate variants (same ancestry, laboratory, classification), generalized linear models for the hereditary breast cancer genes (BRCA1/2) and other variants investigated whether rate of reclassification differed for seven categories of ancestry compared with non-Hispanic European. Models took into account laboratory, year, gene, sex, and current classification (handled as a time-dependent covariate) and were adjusted for multiple hypothesis testing. Results: Among 1483 nonbenign variants, 693 (46.7%) involved BRCA1/2. Overall, 268 (18.1%) variants were reclassified at least once. Few (9.7%) reclassified variants underwent a net upgrade in pathogenicity. For BRCA1/2 variants, reclassification rates varied by ancestry and increased over time, more steeply for ancestries with lower initial rates (African, Ashkenazi, Chinese) than for ancestries whose initial rates were high (Middle Eastern) or similar to non-Hispanic European (non-Chinese Asian, Native American, Hispanic). In contrast, reclassification rates of non-BRCA1/2 variants did not vary over time but were elevated for most minority ancestries except non-Chinese Asian and Native American. Conclusions: For nonbenign variants in cancer-related genes, the rates at which reclassifications are issued vary by ancestry in ways that differ between BRCA1/2 and other genes.
Background: In germline genetic testing, variants from understudied ancestries have been disproportionately classified as being of uncertain significance. We hypothesized that the rate of variant reclassification likewise differs by ancestry. Methods: Nonbenign variants in actionable genes were collected from consenting subjects undergoing genetic testing at two Southern California sites from September 1996 through December 2016. Variant reclassifications were recorded as they were received, until February 2017 or reclassification to benign. Excluding duplicate variants (same ancestry, laboratory, classification), generalized linear models for the hereditary breast cancer genes (BRCA1/2) and other variants investigated whether rate of reclassification differed for seven categories of ancestry compared with non-Hispanic European. Models took into account laboratory, year, gene, sex, and current classification (handled as a time-dependent covariate) and were adjusted for multiple hypothesis testing. Results: Among 1483 nonbenign variants, 693 (46.7%) involved BRCA1/2. Overall, 268 (18.1%) variants were reclassified at least once. Few (9.7%) reclassified variants underwent a net upgrade in pathogenicity. For BRCA1/2 variants, reclassification rates varied by ancestry and increased over time, more steeply for ancestries with lower initial rates (African, Ashkenazi, Chinese) than for ancestries whose initial rates were high (Middle Eastern) or similar to non-Hispanic European (non-Chinese Asian, Native American, Hispanic). In contrast, reclassification rates of non-BRCA1/2 variants did not vary over time but were elevated for most minority ancestries except non-Chinese Asian and Native American. Conclusions: For nonbenign variants in cancer-related genes, the rates at which reclassifications are issued vary by ancestry in ways that differ between BRCA1/2 and other genes.
Authors: J M Eggington; K R Bowles; K Moyes; S Manley; L Esterling; S Sizemore; E Rosenthal; A Theisen; J Saam; C Arnell; D Pruss; J Bennett; L A Burbidge; B Roa; R J Wenstrup Journal: Clin Genet Date: 2013-12-20 Impact factor: 4.438
Authors: Charité Ricker; Julie O Culver; Katrina Lowstuter; Duveen Sturgeon; Julia D Sturgeon; Christopher R Chanock; William J Gauderman; Kevin J McDonnell; Gregory E Idos; Stephen B Gruber Journal: Cancer Genet Date: 2016-01-12
Authors: Arjun K Manrai; Birgit H Funke; Heidi L Rehm; Morten S Olesen; Bradley A Maron; Peter Szolovits; David M Margulies; Joseph Loscalzo; Isaac S Kohane Journal: N Engl J Med Date: 2016-08-18 Impact factor: 91.245
Authors: Allison W Kurian; Yun Li; Ann S Hamilton; Kevin C Ward; Sarah T Hawley; Monica Morrow; M Chandler McLeod; Reshma Jagsi; Steven J Katz Journal: J Clin Oncol Date: 2017-04-12 Impact factor: 50.717
Authors: Thomas Paul Slavin; Mariana Niell-Swiller; Ilana Solomon; Bita Nehoray; Christina Rybak; Kathleen R Blazer; Jeffrey N Weitzel Journal: Front Oncol Date: 2015-09-29 Impact factor: 6.244
Authors: Lisa R Susswein; Megan L Marshall; Rachel Nusbaum; Kristen J Vogel Postula; Scott M Weissman; Lauren Yackowski; Erica M Vaccari; Jeffrey Bissonnette; Jessica K Booker; M Laura Cremona; Federica Gibellini; Patricia D Murphy; Daniel E Pineda-Alvarez; Guido D Pollevick; Zhixiong Xu; Gabi Richard; Sherri Bale; Rachel T Klein; Kathleen S Hruska; Wendy K Chung Journal: Genet Med Date: 2015-12-17 Impact factor: 8.822
Authors: Allison W Kurian; Kevin C Ward; Nadia Howlader; Dennis Deapen; Ann S Hamilton; Angela Mariotto; Daniel Miller; Lynne S Penberthy; Steven J Katz Journal: J Clin Oncol Date: 2019-04-09 Impact factor: 44.544
Authors: Yvonne Bombard; Kyle B Brothers; Sara Fitzgerald-Butt; Nanibaa' A Garrison; Leila Jamal; Cynthia A James; Gail P Jarvik; Jennifer B McCormick; Tanya N Nelson; Kelly E Ormond; Heidi L Rehm; Julie Richer; Emmanuelle Souzeau; Jason L Vassy; Jennifer K Wagner; Howard P Levy Journal: Am J Hum Genet Date: 2019-04-04 Impact factor: 11.025
Authors: Juliann M Savatt; Danielle R Azzariti; David H Ledbetter; Emily Palen; Heidi L Rehm; Erin Rooney Riggs; Christa Lese Martin Journal: Genet Med Date: 2021-05-18 Impact factor: 8.822
Authors: Tess D Pottinger; Megan J Puckelwartz; Lorenzo L Pesce; Avery Robinson; Samuel Kearns; Jennifer A Pacheco; Laura J Rasmussen-Torvik; Maureen E Smith; Rex Chisholm; Elizabeth M McNally Journal: J Am Heart Assoc Date: 2020-02-03 Impact factor: 6.106
Authors: Gregory E Idos; Allison W Kurian; Charité Ricker; Duveen Sturgeon; Julie O Culver; Kerry E Kingham; Rachel Koff; Nicolette M Chun; Courtney Rowe-Teeter; Alexandra P Lebensohn; Peter Levonian; Katrina Lowstuter; Katlyn Partynski; Christine Hong; Meredith A Mills; Iva Petrovchich; Cindy S Ma; Anne-Renee Hartman; Brian Allen; Richard J Wenstrup; Johnathan M Lancaster; Krystal Brown; John Kidd; Brent Evans; Bhramar Mukherjee; Kevin J McDonnell; Uri Ladabaum; James M Ford; Stephen B Gruber Journal: JCO Precis Oncol Date: 2019-03-28